stockrow
Friday 6 November 2026
Export ELAN’s income statement to Excel — free account
Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
23.74
1.57
−6.20%
Follow ELAN
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 4 | 5 | 7 | 1 | 6 | 6 | — | — |
P/E ratio |
0.00 | 17.81 | 0.00 | 0.00 | 0.00 | 0.00 | 155.00 | 134.86 | 0.00 | 0.00 |
P/S ratio |
2.38 | 1.35 | 1.63 | 1.37 | 2.90 | 4.14 | 3.54 | 3.23 | 0.00 | 0.00 |
Altman Z-Score |
1.28 | 0.89 | 0.61 | 0.79 | 1.18 | 0.99 | 2.53 | 2.20 | — | — |
Altman Z″-Score (non-manufacturers) |
1.40 | 1.52 | 0.88 | 1.47 | 1.20 | 1.11 | 3.00 | 2.72 | — | — |
P/FCF ratio |
42.88 | 16.08 | 61.60 | 22.50 | 48.35 | 0.00 | 0.00 | 27.31 | 43.96 | 43.96 |
Beneish M-Score |
(2.68) | (2.64) | (3.00) | (2.67) | (2.78) | (2.47) | (2.34) | (3.94) | (2.73) | — |
P/Operating CF |
104.01 | 33.80 | 45.91 | 463.89 | 62.00 | (145.57) | 86.11 | 70.90 | 77.13 | 77.13 |
P/B ratio |
1.72 | 0.98 | 1.16 | 0.83 | 1.84 | 1.60 | 1.96 | 1.90 | 1.50 | 1.50 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 145.87 | 0.00 | 1.50 | 1.50 |
EV/Sales |
3.12 | 2.22 | 2.86 | 2.61 | 4.09 | 5.86 | 4.19 | 3.81 | 0.00 | 0.00 |
EV/EBITDA |
21.16 | 12.89 | 0.00 | 13.05 | 50.54 | 0.00 | 25.81 | 24.29 | 0.00 | 0.00 |
EV/Operating CF |
26.26 | 18.18 | 46.60 | 25.49 | 40.39 | (467.29) | 57.49 | 23.98 | 28.80 | 28.80 |
EV/FCF |
56.13 | 26.44 | 107.94 | 42.99 | 68.21 | (68.42) | (218.25) | 32.26 | 42.88 | 42.88 |
Quick Ratio |
0.93 | 1.03 | 1.10 | 0.79 | 1.01 | 0.76 | 1.51 | 1.43 | 1.44 | 1.44 |
Current Ratio |
2.17 | 2.44 | 2.75 | 1.93 | 1.99 | 1.65 | 2.90 | 2.58 | 3.30 | 3.15 |
Net Debt/EBITDA |
5.00 | 5.05 | (36.39) | 6.22 | 14.72 | (29.90) | 4.03 | 3.73 | (3.77) | (1.13) |
Debt/Assets |
30.07% | 34.26% | 40.20% | 37.67% | 38.35% | 34.63% | 26.21% | 27.60% | 0.00% | 0.00% |
Debt/Equity |
0.61 | 0.71 | 0.93 | 0.80 | 0.84 | 0.72 | 0.42 | 0.48 | 0.00 | 0.00 |
Asset Turnover |
0.36 | 0.33 | 0.30 | 0.28 | 0.28 | 0.25 | 0.34 | 0.34 | 0.34 | 0.72 |
Operating CF/Net income |
(2.41) | 1.60 | (0.22) | (5.79) | (1.00) | 0.07 | 3.29 | 5.63 | (0.56) | (3.25) |
Capex/Depreciation |
(0.41) | (0.24) | (0.22) | (0.27) | (0.28) | (0.46) | (0.63) | (0.43) | (0.25) | (0.40) |
Interest Coverage |
0.07 | 0.43 | (3.04) | 0.83 | (1.40) | (4.70) | 2.34 | 6.25 | — | — |
| (3.67%) | 5.49% | (18.22%) | (1.05%) | (6.04%) | (8.19%) | 1.27% | 1.33% | (4.20%) | (0.65%) | |
| (1.79%) | 2.51% | (8.25%) | (0.49%) | (2.83%) | (4.30%) | 0.76% | 0.97% | (3.65%) | (1.18%) | |
ROIC |
0.09% | 0.63% | (4.52%) | 0.98% | (1.56%) | (3.13%) | 1.53% | 1.65% | (1.95%) | (0.23%) |
Return on Tangible Assets |
(7.09%) | 11.68% | (38.57%) | (3.03%) | (18.01%) | (21.61%) | 2.71% | 3.52% | (12.94%) | (2.31%) |
Average Days of Receivables |
72.77 | 72.85 | 83.46 | 82.91 | 78.76 | 120.18 | 105.77 | 84.43 | 76.04 | 79.01 |
Research and Development Expense of Revenue |
7.80% | 7.75% | 7.40% | 7.28% | 7.75% | 10.06% | 8.79% | 8.04% | 8.71% | 9.12% |
Selling, General and Administrative Expense of Revenue |
30.33% | 29.60% | 29.09% | 28.68% | 29.45% | 30.48% | 24.75% | 23.97% | 26.99% | 26.94% |
Intangible Assets out of Total Assets |
0.61 | 0.64 | 0.67 | 0.70 | 0.71 | 0.71 | 0.61 | 0.61 | 0.63 | 0.64 |
Share Based Compensation of Revenue |
1.44% | 1.24% | 1.04% | 1.34% | 1.39% | 1.44% | 1.60% | 0.85% | 0.87% | 0.70% |
Graham Net Nets |
(0.30) | (0.55) | (0.66) | (0.82) | (0.41) | (0.43) | (0.10) | (0.13) | 0.18 | 0.18 |
Graham Number |
0.00 | 13.74 | 0.00 | 0.00 | 0.00 | 0.00 | 8.02 | 9.34 | 0.00 | 0.00 |
Earnings Yield |
(2.08%) | 5.62% | (17.08%) | (1.06%) | (3.38%) | (3.91%) | 0.65% | 0.74% | (2.72%) | (2.72%) |
Free Cash Flow Yield |
2.33% | 6.22% | 1.62% | 4.44% | 2.07% | (2.07%) | (0.54%) | 3.66% | 2.27% | 2.27% |
Revenue per Share |
9.50 | 8.99 | 8.97 | 9.03 | 9.78 | 7.41 | 8.32 | 9.78 | 9.85 | 9.93 |
Operating CF per Share |
1.13 | 1.10 | 0.55 | 0.93 | 0.99 | (0.09) | 0.61 | 1.55 | 0.59 | 0.53 |
Capex per Share |
(0.56) | (0.33) | (0.31) | (0.38) | (0.40) | (0.54) | (0.53) | (0.41) | (0.27) | (0.35) |
Free Cash Flow per Share |
0.57 | 0.77 | 0.24 | 0.55 | 0.59 | (0.63) | 0.07 | 1.15 | 0.32 | 0.18 |
Cash per Share |
1.10 | 0.95 | 0.72 | 0.71 | 1.31 | 1.15 | 0.94 | 2.16 | 1.10 | 0.88 |
Shareholders Equity per Share |
13.19 | 12.34 | 12.64 | 14.93 | 15.41 | 19.20 | 15.03 | 16.57 | 26.53 | 23.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
13.19 | 12.34 | 12.64 | 14.93 | 15.41 | 19.20 | 15.03 | 16.57 | 26.53 | 23.96 |
Free Cash Flow |
284.00 | 380.00 | 117.00 | 268.00 | 286.00 | (280.00) | 27.00 | 360.20 | 94.30 | 53.00 |
Working Capital |
1,861.00 | 1,900.00 | 2,166.00 | 1,577.00 | 1,627.00 | 1,340.00 | 1,554.60 | 1,534.20 | 1,480.60 | 1,328.50 |
Capital Expenditures |
(276.00) | (161.00) | (154.00) | (184.00) | (197.00) | (239.00) | (197.00) | (127.10) | (79.50) | (102.90) |
Net Current Asset Value |
(3,353.00) | (3,303.00) | (4,732.00) | (4,923.00) | (5,696.00) | (5,800.00) | (1,065.80) | (1,254.30) | 963.70 | 875.60 |
EV/EBIT |
980.37 | 97.38 | 0.00 | 57.32 | 0.00 | 0.00 | 69.61 | 63.17 | 0.00 | 0.00 |
Capex to Sales |
0.06 | 0.04 | 0.03 | 0.04 | 0.04 | 0.07 | 0.06 | 0.04 | 0.03 | 0.04 |
Price to Operating Income |
748.90 | 59.23 | 0.00 | 30.00 | 0.00 | 0.00 | 58.74 | 53.46 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.48 | 0.67 | 0.68 | 0.68 | 0.68 | 0.39 | 0.33 | 0.32 | 0.35 | 0.34 |
Cash ROIC |
2.56% | 3.49% | 0.95% | 1.99% | 1.98% | (1.85%) | 0.33% | 4.32% | 1.16% | 0.73% |
Accounts Receivable Turnover |
5.16 | 4.68 | 4.39 | 4.35 | 4.53 | 3.33 | 3.84 | 4.68 | 4.69 | 4.73 |
Accounts Payable Turnover |
6.39 | 7.08 | 5.85 | 4.75 | 4.65 | 4.61 | 6.87 | 7.70 | 6.92 | 6.52 |
Inventory Turnover |
1.28 | 1.21 | 1.18 | 1.32 | 1.45 | 1.27 | 1.43 | 1.52 | 1.54 | 1.45 |
Average Days of Payables |
63.30 | 53.94 | 51.04 | 74.41 | 71.22 | 109.70 | 55.27 | 47.59 | 49.79 | 59.12 |
Days of Inventory on Hand |
298.78 | 286.82 | 327.95 | 293.45 | 234.72 | 345.51 | 260.89 | 232.87 | 259.55 | 226.82 |
Average Receivables |
913.00 | 948.00 | 1,006.00 | 1,015.00 | 1,052.50 | 983.45 | 799.65 | 655.65 | 616.30 | 616.35 |
Average Payables |
332.00 | 283.00 | 330.00 | 403.00 | 458.50 | 361.80 | 213.90 | 204.50 | 216.00 | 216.10 |
Average Inventory |
1,655.50 | 1,654.50 | 1,636.50 | 1,454.50 | 1,474.50 | 1,314.35 | 1,027.40 | 1,033.20 | 968.95 | 968.80 |
Average Assets |
12,986.00 | 13,488.00 | 14,926.50 | 15,984.50 | 17,085.50 | 13,339.40 | 8,971.25 | 8,948.50 | 8,520.00 | 4,049.85 |
Average Common Equity |
6,321.50 | 6,159.50 | 6,756.00 | 7,398.50 | 7,992.00 | 7,011.45 | 5,372.20 | 6,488.90 | 7,404.10 | 7,409.45 |
Columns are period end dates